Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplementary File 1 shows the Methods and Results for Part 1B
Preguntar a la IA
Me gusta
Guardar
Compartir
Preguntar a la IA
Me gusta
Guardar
Compartir
Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study | Synapse
Cite This Study
Meric‐Bernstam et al. (Mon,) studied this question.